Organovo (ONVO) Drops 9.84% on January 19

Equities Staff |

Organovo (ONVO) was one of the Russell 2000's biggest losers for Tuesday January 19 as the stock slid 9.84% to $1.70, a loss of $-0.185 per share. Starting at an opening price of $1.90 a share, the stock traded between $1.68 and $1.92 over the course of the trading day. Volume was 1.42 million shares over 3,095 trades, against an average daily volume of 1.02 million shares and a total float of 92.41 million.

The losses send Organovo down to a market cap of $156.64 million. In the last year, Organovo has traded between $6.85 and $1.80, and its 50-day SMA is currently $2.82 and 200-day SMA is $3.54.

Organovo Holdings Inc is a development-stage company. It is engaged in developing and commercializing functional human tissues.

Organovo is based out of San Diego, CA and has some 82 employees. Its CEO is Keith Murphy.

For a complete fundamental analysis analysis of Organovo, check out’s Stock Valuation Analysis report for ONVO. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets


Our mission is to be the best place for people who care about music to create and discover thoughtfully curated playlists. In essence, 8tracks is a platform for online mixtapes.


Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…